Tag: Phase
-
Wave Life Sciences Reports Promising Phase 1 Results for WVE-007: Significant Body Composition Improvement in Obesity Patients
Wave Life Sciences USA, Inc. Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically…
-
Wave Life Sciences to Reveal Interim Data from Phase 1 INLIGHT Trial of WVE-007 for Obesity on December 8, 2025
Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using…
-
U.S. Advances to Phase 2 as Hamas Shows Openness to Disarmament
U.S. seeks move to Phase 2 as Hamas signals willingness to disarm news.cgtn.com An international body tasked with governing Gaza will be announced by the end of year, officials say The New Indian Express Phase two of Trump’s Gaza peace plan faces political gridlock as core governance questions remain unresolved Xinhua Breaking Resistance Through Administration: The Hidden Purpose…
-
Clascoterone 5% Achieves Promising Phase 3 Hair Growth Outcomes
Cosmo Pharmaceuticals has reported encouraging topline findings from 2 large, identically designed phase 3 trials evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). If ultimately approved, the drug could represent the first new therapeutic mechanism for AGA in over 30 years—a notable development for a condition with high prevalence and limited treatment options.1…